<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00310089</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000466185</org_study_id>
    <secondary_id>NCI-06-C-0057</secondary_id>
    <secondary_id>NCI-7088</secondary_id>
    <nct_id>NCT00310089</nct_id>
    <nct_alias>NCT00273923</nct_alias>
  </id_info>
  <brief_title>AZD2171 and Combination Chemotherapy in Treating Women With Locally Advanced Breast Cancer</brief_title>
  <official_title>A Pilot Study to Evaluate The Effects of Neoadjuvant AZD2171, a VEGF Receptor Tyrosine Kinase Inhibitor With Docetaxel, Doxorubicin, and Cyclophosphamide Chemotherapy in Previously Untreated Locally Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth and by blocking blood flow to the tumor. Drugs used in chemotherapy, such as&#xD;
      doxorubicin, cyclophosphamide, and docetaxel, work in different ways to stop the growth of&#xD;
      tumor cells, either by killing the cells or by stopping them from dividing. Giving AZD2171&#xD;
      together with combination chemotherapy before surgery may make the tumor smaller and reduce&#xD;
      the amount of normal tissue that needs to be removed and may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: This randomized clinical trial is studying how well giving AZD2171 together with&#xD;
      combination chemotherapy works in treating women with locally advanced breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the overall pathologic complete response rate in women with previously&#xD;
           untreated, locally advanced breast cancer treated with neoadjuvant AZD2171, doxorubicin&#xD;
           hydrochloride, cyclophosphamide, and docetaxel.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Compare changes in pretreatment levels of pKDR after 1 course of AZD2171 vs no&#xD;
           medication.&#xD;
&#xD;
        -  Determine the number of patients who respond to combination therapy beginning with the&#xD;
           second course of therapy.&#xD;
&#xD;
        -  Determine the clinical response rate in patients treated with this regimen.&#xD;
&#xD;
        -  Determine the safety of this regimen in these patients.&#xD;
&#xD;
        -  Determine the changes in tumor proliferation (Ki67) in these patients.&#xD;
&#xD;
        -  Determine the pharmacokinetics and pharmacogenetics of this regimen in these patients.&#xD;
&#xD;
        -  Correlate angiogenic parameters with tumor response in these patients.&#xD;
&#xD;
        -  Determine tumor vascularity and permeability before and after treatment as seen on&#xD;
           dynamic contrast-enhanced MRI and initial area under the gadolinium curve.&#xD;
&#xD;
        -  Determine tumor choline levels before and after treatment as measured by quantitative&#xD;
           single-voxel MR spectroscopy and correlate with response.&#xD;
&#xD;
      OUTLINE: This is a multicenter, randomized, pilot study. Patients are randomized to 1 of 2&#xD;
      treatment arms.&#xD;
&#xD;
        -  Arm I: Patients receive oral AZD2171 once daily on days 1-7* during course 1. During the&#xD;
           second and subsequent courses, patients receive oral AZD2171 once daily on days 1-21,&#xD;
           doxorubicin hydrochloride IV over 3-5 minutes, cyclophosphamide IV over 30 minutes, and&#xD;
           docetaxel IV over 1 hour on day 1. Patients also receive filgrastim (G-CSF)&#xD;
           subcutaneously (SC) on days 2-11 or pegfilgrastim SC on day 2. Treatment repeats every 3&#xD;
           weeks for up to 6 courses in the absence of disease progression or unacceptable&#xD;
           toxicity.&#xD;
&#xD;
      NOTE: *If biopsy cannot be scheduled prior to day 7 or 8 of course 1, AZD2171 alone can be&#xD;
      continued for up to 14 days.&#xD;
&#xD;
        -  Arm II (control): Beginning during the second course, patients receive AZD2171,&#xD;
           doxorubicin hydrochloride, cyclophosphamide, docetaxel, and G-CSF or pegfilgrastim as in&#xD;
           arm I.&#xD;
&#xD;
      All patients undergo tumor biopsiesat at baseline, before courses 2 and 4, and 3 weels after&#xD;
      completion of study treatment. Tissue is examined for various biomarkers (phosphorylated-KDR,&#xD;
      -MAPK, and -Akt, Ki67, VEGF, and p53) and for DNA ploidy analysis**.&#xD;
&#xD;
      NOTE: **Patients also undergo dynamic contrast-enhanced MRI and quantitative magnetic&#xD;
      resonance spectroscopy 1 week before beginning therapy, 24 hours after starting therapy,&#xD;
      prior to courses 2, 4, and 6, and 3 weeks after completion of study treatment.&#xD;
&#xD;
      After completion of AZD2171 and chemotherapy, patients undergo surgical resection.&#xD;
&#xD;
      After completion of study treatment, patients are followed for 4 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">July 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <enrollment type="Anticipated">33</enrollment>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pegfilgrastim</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cediranib maleate</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>doxorubicin hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>neoadjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast cancer, meeting 1 of the following&#xD;
             criteria:&#xD;
&#xD;
               -  Previously untreated disease&#xD;
&#xD;
               -  Inflammatory disease&#xD;
&#xD;
               -  Locally advanced breast cancer (stage IIIA, IIIB, or IIIC disease)&#xD;
&#xD;
          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion (longest&#xD;
             diameter) ≥ 20 mm by conventional techniques or ≥ 10 mm by spiral CT scan or breast&#xD;
             MRI&#xD;
&#xD;
          -  Accessible tumor tissue for serial biopsy&#xD;
&#xD;
          -  No overexpression of HER2&#xD;
&#xD;
          -  No known brain metastases secondary to breast cancer&#xD;
&#xD;
          -  Hormone receptor status not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Karnofsky performance status 60-100%&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  Female only&#xD;
&#xD;
          -  Menopausal status not specified&#xD;
&#xD;
          -  Absolute neutrophil count ≥ 1,000/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL&#xD;
&#xD;
          -  Bilirubin normal (≤ 2 times upper limit of normal [ULN] if evidence of Gilbert's&#xD;
             disease and elevated bilirubin not related to tumor or other liver disease)&#xD;
&#xD;
          -  AST and ALT ≤ 2.5 ULN&#xD;
&#xD;
          -  Creatinine normal OR creatinine clearance ≥ 60 mL/min&#xD;
&#xD;
          -  Proteinurea ≤ +1 on 2 consecutive dipsticks at least 1 week apart&#xD;
&#xD;
          -  INR ≤ 1.5&#xD;
&#xD;
          -  LVEF ≥ 50% by MUGA or echocardiogram without clinical symptoms or signs of heart&#xD;
             failure&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  No peripheral neuropathy ≥ grade 2&#xD;
&#xD;
          -  No known CNS disease, including history of stroke or seizures not controlled by&#xD;
             standard medical therapy&#xD;
&#xD;
          -  No history of allergic reactions attributed to compounds of similar chemical or&#xD;
             biologic composition to docetaxel, doxorubicin hydrochloride, or cyclophosphamide&#xD;
&#xD;
          -  No uncontrolled intercurrent illness including, but not limited to, any of the&#xD;
             following:&#xD;
&#xD;
               -  Hypertension&#xD;
&#xD;
               -  Ongoing or active infection requiring IV antibiotics&#xD;
&#xD;
               -  Symptomatic congestive heart failure&#xD;
&#xD;
               -  Unstable angina pectoris&#xD;
&#xD;
               -  Cardiac arrhythmia&#xD;
&#xD;
               -  Peripheral vascular disease ≥ grade II&#xD;
&#xD;
               -  Psychiatric illness/social situation that would preclude study treatment&#xD;
&#xD;
          -  No nonhealing wounds or bone fractures within the past 28 days&#xD;
&#xD;
          -  No history of an active malignancy except carcinoma in situ of the cervix or&#xD;
             nonmelanomatous skin cancer in the past 5 years&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No prior surgery, chemotherapy, or hormonal therapy for breast cancer&#xD;
&#xD;
          -  No concurrent medication that may affect renal function (e.g., amphotericin B or&#xD;
             pentamidine)&#xD;
&#xD;
          -  No full-dose oral or parenteral anticoagulants or chronic daily treatment with aspirin&#xD;
             (dose &gt; 325 mg/day) within the past 10 days&#xD;
&#xD;
          -  No other concurrent investigational agents&#xD;
&#xD;
          -  No other concurrent commercially available drugs for this cancer&#xD;
&#xD;
          -  No concurrent antiretroviral therapy for known HIV infection&#xD;
&#xD;
          -  No major surgery within the past 28 days&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Neelima Denduluri, MD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892-1182</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2007</verification_date>
  <study_first_submitted>March 29, 2006</study_first_submitted>
  <study_first_submitted_qc>March 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 3, 2006</study_first_posted>
  <last_update_submitted>June 18, 2013</last_update_submitted>
  <last_update_submitted_qc>June 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 20, 2013</last_update_posted>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>inflammatory breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Cediranib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

